US Patent Issued to The General Hospital on Feb. 3 for "HSP fusion protein with anti-chemorepellant agent for treatment of cancer" (Massachusetts Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,165, issued on Feb. 3, was assigned to The General Hospital Corp. (Boston).

"HSP fusion protein with anti-chemorepellant agent for treatment of cancer" was invented by Mark C. Poznansky (Newton, Mass.) and Jeffrey A. Gelfand (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain."

The patent was filed on May 9, 2022, under Application No. 17/739,444.

*For ...